New Medication Based on Cell Therapy developed by Hadassah Doctor Helps Severe and Critical COVID-19 patients at HMO Today the fifth of 5 COVID-19 intensive care patients, who received an experimental treatment with human cells was discharged. The 5 are healthy and are negative for the coronavirus. The drug "Allocerta", based on human cells donated by healthy individuals, was developed at Hadassah, together with the bio-tech company Enlivex. This is the first clinical trial in the world treating coronavirus patients with human cells taken from live donors. The patients were discharged, on average, 5-6 days following receipt of the drug. Allocerta was developed based on the research of Prof. Dror Mevorach, Head of Internal Medicine B and one of Hadassah's coronavirus wards. The drug has already successfully been given to 10 sepsis patients. Allocerta was developed to treat a wide range of patients who have over-active immune systems leading to increased secretion of proteins called cytokines that cause a "cytokine storm". Cells taken from a healthy donor are engineered in the laboratory is such a way that with their injection into the patient's body they control the inflammation or the cytokine storm. The clinical trial in coronavirus patients is led by Prof. Vernon van Herdeen, Head of General Intensive Care at Hadassah Ein Kerem and has the approval of the Ministry of Health's Helsinki Committee. Subscribe to our newsletter to keep up-to-date with the latest news from Hadassah Hospital.